Clinical Report: Successful Management of Latent Autoimmune Diabetes in Two Young Women Using Oral Semaglutide and Basal Insulin

Overview

This case series presents two young women with latent autoimmune diabetes in youth (LADY) managed with oral semaglutide and basal insulin. Both patients achieved glycemic control and weight loss.

Background

Latent autoimmune diabetes in youth (LADY) is a form of autoimmune diabetes that typically presents between the ages of 8 and 29, characterized by slow progression to insulin dependence. This condition can lead to diagnostic challenges and may require tailored therapeutic strategies. Understanding effective management options is crucial for improving outcomes in this patient population.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• Case 1: A 20-year-old woman achieved significant weight loss (−20 kg) and resolution of liver steatosis after 12 months on oral semaglutide and basal insulin.
• Case 2: A 13-year-old girl maintained glycemic control and increased C-peptide levels after transitioning to oral semaglutide.
• Both patients had high-titer multiple diabetes-related autoantibodies but preserved C-peptide levels.
• This case series presents the use of oral semaglutide in managing LADY.
• Semaglutide treatment also showed potential benefits for metabolic dysfunction-associated steatotic liver disease (MASLD).

Clinical Implications

The management of LADY with oral semaglutide and basal insulin may provide insights for treating similar patients.

Conclusion

This case series provides evidence for the use of oral semaglutide in managing LADY, with outcomes in glycemic control and weight loss.

Related Resources & Content

1. Frontiers in Endocrinology, 2026 -- Case reports: Latent Autoimmune Diabetes in two Young Females Successfully Treated with Oral Semaglutide and Basal Insulin
2. The Journal of Clinical Endocrinology & Metabolism — Efficacy of Tirzepatide, a Dual GIP/GLP-1 Agonist, in Two Patients with Alström Syndrome, a Rare Form of Obesity
3. Ophthalmology Management — Additional Ophthalmic Complications Associated With GLP1 Use Identified in Case Series
4. The Journal of Clinical Endocrinology & Metabolism — Enhancement of β-Cell Function Following Transition from DPP-4 Inhibitors to Oral Semaglutide: A Post Hoc Analysis of SWITCH-SEMA2
5. Obesity and Endocrinology — Addressing Obesity to Prevent Diabetes: A Comprehensive STEP-by-STEP Examination of a Challenging Issue
6. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
7. Latent autoimmune diabetes in youth - PubMed
8. Semaglutide in Adults with Type 1 Diabetes and Obesity - PubMed
9. A Case of Slowly Progressive Type 1 Diabetes Mellitus (SPIDDM, Probable) Successfully Managed With Oral Semaglutide for Glycemic Control and Weight Management Accompanied by Changes in Eating Behavior - PubMed
10. Frontiers | Case reports: Latent Autoimmune Diabetes in two Young Females Successfully Treated with Oral Semaglutide and Basal Insulin